Independent Health & Biomedical Research

Achs et al. (npj Vaccines, December 2025) concluded no excessive DNA impurities and no host-genome carryover. An independent re-mapping of the sequencing data they deposited (PRJNA1303864) shows the second conclusion is false and the first is contested on its own arithmetic: near-complete E. coli genomic DNA in four of five Comirnaty lots at 1.4-2.4 percent of all reads (96 percent genome breadth, 56-95x mean depth), whole circular plasmid in every lot, and an RNA:DNA hybrid footprint in their own fragment lengths. The method critique is McKernan, Speicher and Rose's. The deposit analysis is what this article adds.

In October 2023 the EMA's Biologics Working Party put two investigations in writing with a 1 December 2023 completion date: analytical characterisation of residual DNA including fragment sizes, intact circular plasmid and SV40 sequences, and bacterial transformation capability. Part of that programme is now public. The rest, including the transformation testing, the batch-level dataset and any reassessment after Achs et al. (2025), is not. This page gives you the questions to file with eight authorities, written to be answered, plus the route for filing each one.

Using the EMA's own BWP position paper (released under ASK-289849) and the public GenBank deposit OR134577.1, an independent annotation of the BNT162b2 plasmid. The SV40 footprint is 695 bp, the backbone traces to the 1981 pSV2 vector family, and the integration property has been documented for 45 years.

Guide to nobiletin and eriodictyol, potent citrus flavonoids that combat inflammation, support antioxidant defenses, and attenuate endotoxin-induced inflammatory signaling.

Your biology is unique. What helps one person recover may not help you or could make things worse. This framework guides you through systematic assessment and targeted interventions based on your specific health terrain.

The fenbendazole story graded from the origin to 2026: one man's clean scan with an acknowledged confound, real mechanisms (microtubules, p53 activation), one systematic review with actual human data in brain tumours, and the most-shared 'human evidence' paper now under Expression of Concern.

The exosome relay article ended on a lever it never examined: if vesicles are a transport layer, does anything turn vesicle release down? CBD is the best-studied release inhibitor in the cell-culture literature. The release findings, the autophagy arm underneath them, the entry-blockade arm beside them, and the junction with vaccine-derived vesicles that nobody has measured. With the cannabis-genomics side of Kevin McKernan's work on what a real product is.

ApoE4 carriers ask whether these products treat them differently. The question decomposes into a five-link chain: the corona is ApoE-rich and merges into the particle by fusion; ApoE is a demonstrated endogenous targeting ligand for ionizable LNPs; receptor binding is isoform-sensitive in principle; the single human genotype-stratified study was null and its power cannot be assessed from the abstract; and E4-specific corona composition has never been measured anywhere. This article walks each link at its verified grade, names the one weak weld in the chain (the siRNA-to-vaccine-lipid bridge), and states what would have to be true for the honest answer to change.

The site's forensics cluster documents what got into the vials. The persistence cluster documents what spike does once it is made. The missing layer has always been the particle itself. This article assembles the lipid-nanoparticle evidence: how LNPs acquire a biological identity in lymph and plasma, why distribution follows capillary anatomy rather than diffusion, what the regulatory and published pharmacokinetic studies actually measured, why the empty fraction of every batch is biologically active, and what the Gutschi, Seger and Seneff active-biointerface review proposes. Every load-bearing claim carries a verified primary source.

A six-ground retraction request against Andersen et al. (2020), 'The proximal origin of SARS-CoV-2', under the COPE guidelines, prepared for Nature Medicine and published here before it is filed. The documentary case rests on the July 2026 Senate release of the authors' private Slack channel and the Baric transcribed interview. Spun out from the Pinsolle Framework article, where the underlying evidence is presented.

Spike detectable weeks after injection does not require genomic integration or an immortal producer cell. Maria Gutschi's Index, Persistence, Relay frame, checked against the primary literature: a finite template (Röltgen), durable protein deposits (Ogata, Röltgen), and a measured vesicle exit route (Sahay, Maugeri, Bansal). With two calibrated corrections to the analog numbers the frame is usually quoted with.